November 16, 2026
Source: drugdu
44

Why hasn't the highly anticipated bispecific antibody, Akeso and Summit, received FDA approval? How far are Chinese innovative drugs from going global?
On November 15, 2026, the U.S. FDA announced that its initial application for marketing approval in the United States for ivonescimab, an anticancer drug developed by China's Akeso Biopharma and partially commercialized in overseas markets by Summit Therapeutics in the United States, was rejected. The FDA issued a Complete Response Letter (CRL), stating that the existing data was insufficient to support approval, and the applicant company could submit supplementary evidence and reapply. The reason can be summarized as follows: the FDA believed that the improvement in progression-free survival (PFS) was insufficient to compensate for the uncertainty in overall survival (OS) evidence, and that the overall benefit could not be confirmed to outweigh the risks. While the drug demonstrated the ability to delay cancer progression, it failed to sufficiently demonstrate, according to pre-defined statistical standards, that patients could live longer.
Disappointment, persistence, and caution of pharmaceutical company management
The news has attracted widespread attention because evoxisumab is one of the earliest PD-1/VEGF bispecific antibodies to undergo large-scale clinical trials globally. In a head-to-head study conducted in China, it outperformed Merck's Keytruda (pembrolizumab), the world's best-selling anticancer drug. AstraZeneca also announced a $2 billion investment in Summit in September 2026, precisely because of evoxisumab's potential.
Summit Chairman and Co-CEO Robert Duggan told Fierce Pharma that the company was disappointed that it could not deliver good news to patients awaiting new treatment options. However, he emphasized that Summit and Akeso have achieved positive results in five Phase III studies, and the company's confidence in evoximab and its determination to continue its development remain unchanged.
AstraZeneca's stance in this incident is noteworthy. In September 2026, AstraZeneca announced a $2 billion investment in Summit and plans to explore combination therapy between evoxisumab and its ADC. Susan Galbraith, Head of Oncology and Hematology Research at AstraZeneca, stated that PD-1/VEGF bispecific antibodies have the potential to improve existing immunotherapies, particularly in lung cancer, breast cancer, and gastrointestinal tumors.
Why hasn't it been approved yet, given that cancer has been controlled for longer periods?
This US marketing application is primarily based on the global Phase III clinical trial of HARMONi. The study included patients with advanced non-squamous non-small cell lung cancer who had developed resistance to third-generation EGFR-targeted therapies. Treatment for these patients is challenging, and after first-line targeted therapy fails, the available effective treatment options are relatively limited.
The HARMONi study enrolled 438 patients, comparing edoximumab in combination with chemotherapy versus chemotherapy alone. Results showed a median progression-free survival (PFS) of 6.8 months in the edoximumab plus chemotherapy group and 4.4 months in the control group; the risk of disease progression or death was reduced by approximately 48%. This is a considerable figure. However, another issue of concern to the FDA is whether delayed cancer progression ultimately leads to longer survival. This relates to overall survival (OS), which is the time from the start of the study to death.
The initial analysis of the HARMONi study found that the median overall survival (OS) in the evosimib group was 16.8 months, compared to 14.0 months in the control group, seemingly a 2.8-month extension. However, the pre-designed statistical test did not reach the significance threshold, with a p-value of 0.057, which was higher than the pre-defined significance limit for this analysis.
Subsequently, with extended observation periods, Summit released further results. In the all-patient analysis updated in June 2026, the OS hazard ratio improved to 0.76, with a nominal P-value of 0.0151. This indicates that the data continues to develop in a favorable direction, but it is a follow-up exploratory analysis and cannot simply replace the completed pre-specified primary analysis. Therefore, the FDA believes that the existing data are still insufficient to demonstrate a clear and reliable overall benefit for this specific indication. In other words, the FDA did not assert that evoxisumab is completely incapable of prolonging life, but rather that the company failed to adequately demonstrate this as required. There is an important distinction between the two.
Why have Kangfang's antibodies attracted global attention?
Back in 2024, Akeso Biopharma released clinical trial data for HARMONi-2. This study compared evokimab with Keytruda in certain patients with PD-L1-positive advanced non-small cell lung cancer who had received prior systemic therapy.
The preliminary results are noteworthy. Patients receiving evoxisumab had a median progression-free survival (PFS) of 11.1 months, compared to 5.8 months in the Keytruda group. Evoxisumab prolonged the duration of disease control. It should be noted that 11.1 months and 5.8 months are median values and not the actual time achieved by each patient.
Further data released in September 2026 showed that in this study, which was conducted entirely in China, the median overall survival (OS) was 30.8 months in the ewocizumab group and 22.6 months in the Keytruda group, a difference of 8.2 months; the relative reduction in the risk of death was approximately 27%, meeting the pre-defined statistical significance criteria.
This is a significant achievement. Keytruda has long held a prominent position in the global anti-cancer drug market, and obtaining better clinical data in direct comparison demonstrates that China's innovative drug development capabilities are considerable. However, this trial has a significant limitation: all 398 participants were from China. It demonstrates the clinical benefit of evosimib in these Chinese patients, but it cannot automatically prove that patients in the United States and Europe will experience the same efficacy.
Has the FDA raised its approval standards?
This incident has sparked another discussion in the media: Is the US FDA tightening its approval process for new cancer drugs?
In February 2026, FDA senior officials Martin Makary and Vinay Prasad proposed that future drug approvals could increasingly adopt a model of "one rigorous pivotal clinical trial plus other confirmatory evidence," rather than mechanically requiring two independent trials. This seems to imply that the FDA will reduce the difficulty of approving new drugs. However, the reality is not so simple. While the number of clinical trials can be reduced, the scientific quality of each study, the selection of control groups, statistical design, and the reliability of evidence remain extremely important.
This does not contradict the case of evosimib. The FDA has not announced that all new anticancer drugs will henceforth be approved solely based on overall survival (OS). In fact, in some cases, progression-free survival (PFS) or other recognized surrogate endpoints can support routine or accelerated approval. However, in this application, the FDA argued that the improvement in PFS was insufficient to compensate for the uncertainty in OS evidence, and therefore could not confirm that the overall benefit outweighed the risks. The FDA emphasized that it is not enough to simply consider how much a drug can shrink a tumor; the actual benefit ultimately obtained by the patient must also be measured.
Kangfang Bio has not failed.
While the failure to obtain FDA approval is indeed disappointing, it cannot erase the previous achievements of evoxicomab.
First, evosimib has already received approval for multiple lung cancer indications in China. Second, it has achieved positive results in other studies. However, it must be noted that HARMONi-6 and HARMONi-2 were both studies conducted in China, and their enrolled patients, treatment phases, and control drugs differ from the global HARMONi studies currently under FDA review.
The same applies to the commercial aspect. In 2022, Akeso licensed the development and commercialization rights of evoxicomab in the US, Canada, Europe, Japan, and other markets to Summit. The potential total transaction amount was up to $5 billion, plus sales royalties. This setback in the US approval process will affect the overseas listing timeline and commercial prospects, but it does not mean that Akeso will have to refund the initial licensing payment it has already received, nor will it directly terminate sales in the Chinese market.
On the other hand, companies such as AstraZeneca and GSK are still exploring opportunities to combine evoximab with next-generation drugs, with ADCs (antibody-drug conjugates) attracting particular attention. In the future, combining the cancer-killing effects of ADCs with the immune-modulating effects of evoximab may yield even better therapeutic outcomes.
What is lacking in the export of Chinese innovative drugs?
Experts have commented that over the past decade, an increasing number of Chinese companies have begun developing first-in-class drugs. Akeso Biopharma's PD-1/VEGF bispecific antibody is a prime example of this transformation. However, truly entering the US and European markets requires addressing the issue of internationalizing clinical research. "For example, if US patient enrollment begins too late, even if the total number of participants meets the requirements, data immaturity may arise during pivotal analyses." Another lesson is that one cannot over-rely on a single, particularly ideal indicator. While prolonged PFS may indeed improve the patient experience and has clinical value, if companies describe it as evidence that the drug comprehensively surpasses existing treatments, but cannot prove that patients live longer, regulatory agencies and the clinical community will naturally raise questions.
Furthermore, for companies like Summit that heavily rely on a single blockbuster drug, a single registration setback can jeopardize their entire business plan. Large multinational pharmaceutical companies are willing to invest heavily not just to acquire a promising molecule, but also to secure a significant position in the future therapeutic market.
Currently, companies such as Pfizer, Merck, and Bristol-Myers Squibb are all advancing related PD-1/VEGF or PD-L1/VEGF bispecific antibody projects. This means that evoxisumab cannot wait indefinitely; its future competitive advantage must be demonstrated through new global clinical data.
For Summit and Akeso, the next more important study may be HARMONi-3. This global study evaluates edoximumab in combination with chemotherapy as first-line treatment for advanced non-small cell lung cancer, comparing it with the standard of care based on Keytruda. Evoximab still has the opportunity to enter the most important area of lung cancer treatment globally. However, as of November 15, 2026, the key results of this study have not yet been fully published, and its success remains uncertain.
Source: https://mp.weixin.qq.com/s?__biz=MzAwNzMyNzQzNg==&mid=2650672190&idx=1&sn=b8436c4ffe4c942887affff2c9c6815c&chksm=825b77e0d1339434e4a7d40216b6de0dd42ea2c1e9b9cd1c1757e8974427d782db2b45b25878&scene=126&sessionid=0#rd
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.